All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
REACH2: What patients with steroid-refractory acute GvHD respond best to ruxolitinib?
Bookmark this article
During the 25th Congress of the European Hematology Association (EHA), the GvHD Hub spoke to Robert Zeiser, Medical Center – University of Freiburg, Freiburg, DE about the REACH2 clinical trial. REACH 2 is a phase III study evaluating ruxolitinib vs best available therapy in patients with corticosteroid-refractory acute GvHD following allogeneic stem cell transplantation.
We asked: What patients with steroid-refractory acute GvHD respond best to ruxolitinib?
REACH2: What patients with steroid-refractory acute GvHD respond best to ruxolitinib?
Related articles
Newsletter
Subscribe to get the best content related to GvHD delivered to your inbox